Advances in LLM: Rituximab as therapy for acute lymphoblastic leukemia

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 3, 2010, Pages 168-171

  Thomas, Deborah A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ARZERRA; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; IMATINIB; MONOCLONAL ANTIBODY; NELARABINE; OFATUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BURKITT LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; KARYOTYPE; LIVER FAILURE; NONHODGKIN LYMPHOMA; PATIENT CARE; PEDIATRICS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; T CELL LEUKEMIA; TUMOR LYSIS SYNDROME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, B-CELL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77950813669     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646-1654.
2. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lym-phoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
3. de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult proto-cols in the Netherlands. Leukemia. 2004;18:2032-2035.
4. Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adoles-cents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AEIOP) and adult (GIMEMA) protocols. Blood (ASH Annual Meeting Abstracts). 2004;104:Abstract 1954.
5. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lympho-blastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKAL-LXII/E2993) trials. Pediatr Blood Cancer. 2007;48:254-261.
6. Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic leukemia in adoles-cents and young adults in Finland. Haematologica. 2008;93:1161-1168.
7. Thomas DA, Rytting M, O'Brien S, et al. Outcome for adolescents and young adults (AYA) with the hyper-CVAD (with or without rituximab) regimens for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 3084.
8. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911-918.
9. Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program. 2007;435-443.
10. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lym-phoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580.
11. Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluo-rescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood. 1997;89: 3960-3966.
12. Jeha S, Behm F, Pei D, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006;108:3302-3304.
13. Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leuke-mia. Blood. 2009;113:6330-6337.
14. Thomas DA, Kantarjian HM, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome for patients with de novo Philadelphia negative precursor B-cell acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 236.
15. Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:949-971.
16. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with ritux-imab in adult CD20 B-precusor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT. Haematologica. 2009;94: Abstract 481.
17. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy-rare but there! Leuk Lymphoma. 2009;50:1083-1095.
18. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs. 2009;18:491-500.
19. Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50:886-891.
20. d'Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res. 2009; 33:465-473.
21. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007;25:813-819.
22. DeAngelo DJ, Silverman LB, Couban S, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lympho-blastic leukemia. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 1858.
23. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treat-ment of adolescents and young adults with standard-risk acute lymphoblastic leu-kemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26:1843-1849.
24. Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146:76-85.
25. Rytting M, Thomas DA, Franklin A, et al. Pediatric-based therapy for young adults with newly diagnosed lymphoblastic leukemia. Blood (ASH Annual Meet-ing Abstracts). 2009;114:Abstract 2037.
26. Faderl S, Thomas DA, Koller CA, et al. Hyper-CVAD plus nelarabine: apilot study for patients with newly diagnosed T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL). Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 3960.
27. Ravandi F, Kantarjian HM, Thomas DA, et al. Phase II study of combina-tion of the hyper-CVAD regimen with dasatinib in front line therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2009;114:Abstract 837.